Building Capacity for the Assessment of HIV Drug Resistance: Experiences From the PharmAccess African Studies to Evaluate Resistance Network

Raph L. Hamers; Elske Straatsma; Cissy Kityo; Carole L. Wallis; Wendy S. Stevens; Kim C. E. Sigaloff; Margaret Siwale; Francesca Conradie; Mariette E. Botes; Kishor Mandaliya; Maureen Wellington; Akin Osibogun; Michèle van Vugt; Tobias F. Rinke de Wit; Michle Van Vugt

doi:10.1093/cid/cir995

Building Capacity for the Assessment of HIV Drug Resistance: Experiences From the PharmAccess African Studies to Evaluate Resistance Network

Raph L. Hamers
, Elske Straatsma
, Cissy Kityo
, Carole L. Wallis
, Wendy S. Stevens
, Kim C. E. Sigaloff
, Margaret Siwale
, Francesca Conradie
, Mariette E. Botes
, Kishor Mandaliya
, Maureen Wellington
, Akin Osibogun
, Michèle van Vugt
, Tobias F. Rinke de Wit
, Michle Van Vugt

Academic Medical Centre, University of Amsterdam
Joint Clinical Research Centre
University of the Witwatersrand
Lusaka Trust Hospital
Muelmed Hospital
Coast Province General Hospital
Newlands Clinic
Lagos State University

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The PharmAccess African Studies to Evaluate Resistance (PASER) network was established as a collaborative partnership of clinical sites, laboratories, and research groups in 6 African countries; its purpose is to build research and laboratory capacity in support of a coordinated effort to assess population-level acquired and transmitted human immunodeficiency virus type-1 drug resistance (HIVDR), thus contributing to the goals of the World Health Organization Global HIV Drug Resistance Network. PASER disseminates information to medical professionals and policy makers and conducts observational research related to HIVDR. The sustainability of the network is challenged by funding limitations, constraints in human resources, a vulnerable general health infrastructure, and high cost and complexity of molecular diagnostic testing. This report highlights experiences and challenges in the PASER network from 2006 to 2010

Original language	English
Pages (from-to)	S261-S265
Journal	Clinical infectious diseases
Volume	54
Issue number	4
DOIs	https://doi.org/10.1093/cid/cir995
Publication status	Published - 15 May 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1093/cid/cir995

Cite this

Hamers, R. L., Straatsma, E., Kityo, C., Wallis, C. L., Stevens, W. S., Sigaloff, K. C. E., Siwale, M., Conradie, F., Botes, M. E., Mandaliya, K., Wellington, M., Osibogun, A., van Vugt, M., Rinke de Wit, T. F., & Van Vugt, M. (2012). Building Capacity for the Assessment of HIV Drug Resistance: Experiences From the PharmAccess African Studies to Evaluate Resistance Network. Clinical infectious diseases, 54(4), S261-S265. https://doi.org/10.1093/cid/cir995

@article{6c435dbfea44410c9a9c124592cbf103,

title = "Building Capacity for the Assessment of HIV Drug Resistance: Experiences From the PharmAccess African Studies to Evaluate Resistance Network",

abstract = "The PharmAccess African Studies to Evaluate Resistance (PASER) network was established as a collaborative partnership of clinical sites, laboratories, and research groups in 6 African countries; its purpose is to build research and laboratory capacity in support of a coordinated effort to assess population-level acquired and transmitted human immunodeficiency virus type-1 drug resistance (HIVDR), thus contributing to the goals of the World Health Organization Global HIV Drug Resistance Network. PASER disseminates information to medical professionals and policy makers and conducts observational research related to HIVDR. The sustainability of the network is challenged by funding limitations, constraints in human resources, a vulnerable general health infrastructure, and high cost and complexity of molecular diagnostic testing. This report highlights experiences and challenges in the PASER network from 2006 to 2010",

author = "Hamers, \{Raph L.\} and Elske Straatsma and Cissy Kityo and Wallis, \{Carole L.\} and Stevens, \{Wendy S.\} and Sigaloff, \{Kim C. E.\} and Margaret Siwale and Francesca Conradie and Botes, \{Mariette E.\} and Kishor Mandaliya and Maureen Wellington and Akin Osibogun and \{van Vugt\}, Mich{\`e}le and \{Rinke de Wit\}, \{Tobias F.\} and \{Van Vugt\}, Michle",

year = "2012",

month = may,

day = "15",

doi = "10.1093/cid/cir995",

language = "English",

volume = "54",

pages = "S261--S265",

journal = "Clinical infectious diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "4",

}

Hamers, RL, Straatsma, E, Kityo, C, Wallis, CL, Stevens, WS, Sigaloff, KCE, Siwale, M, Conradie, F, Botes, ME, Mandaliya, K, Wellington, M, Osibogun, A, van Vugt, M , Rinke de Wit, TF & Van Vugt, M 2012, 'Building Capacity for the Assessment of HIV Drug Resistance: Experiences From the PharmAccess African Studies to Evaluate Resistance Network', Clinical infectious diseases, vol. 54, no. 4, pp. S261-S265. https://doi.org/10.1093/cid/cir995

TY - JOUR

T1 - Building Capacity for the Assessment of HIV Drug Resistance

T2 - Experiences From the PharmAccess African Studies to Evaluate Resistance Network

AU - Hamers, Raph L.

AU - Straatsma, Elske

AU - Kityo, Cissy

AU - Wallis, Carole L.

AU - Stevens, Wendy S.

AU - Sigaloff, Kim C. E.

AU - Siwale, Margaret

AU - Conradie, Francesca

AU - Botes, Mariette E.

AU - Mandaliya, Kishor

AU - Wellington, Maureen

AU - Osibogun, Akin

AU - van Vugt, Michèle

AU - Rinke de Wit, Tobias F.

AU - Van Vugt, Michle

PY - 2012/5/15

Y1 - 2012/5/15

N2 - The PharmAccess African Studies to Evaluate Resistance (PASER) network was established as a collaborative partnership of clinical sites, laboratories, and research groups in 6 African countries; its purpose is to build research and laboratory capacity in support of a coordinated effort to assess population-level acquired and transmitted human immunodeficiency virus type-1 drug resistance (HIVDR), thus contributing to the goals of the World Health Organization Global HIV Drug Resistance Network. PASER disseminates information to medical professionals and policy makers and conducts observational research related to HIVDR. The sustainability of the network is challenged by funding limitations, constraints in human resources, a vulnerable general health infrastructure, and high cost and complexity of molecular diagnostic testing. This report highlights experiences and challenges in the PASER network from 2006 to 2010

AB - The PharmAccess African Studies to Evaluate Resistance (PASER) network was established as a collaborative partnership of clinical sites, laboratories, and research groups in 6 African countries; its purpose is to build research and laboratory capacity in support of a coordinated effort to assess population-level acquired and transmitted human immunodeficiency virus type-1 drug resistance (HIVDR), thus contributing to the goals of the World Health Organization Global HIV Drug Resistance Network. PASER disseminates information to medical professionals and policy makers and conducts observational research related to HIVDR. The sustainability of the network is challenged by funding limitations, constraints in human resources, a vulnerable general health infrastructure, and high cost and complexity of molecular diagnostic testing. This report highlights experiences and challenges in the PASER network from 2006 to 2010

UR - https://www.scopus.com/pages/publications/84860360727

U2 - 10.1093/cid/cir995

DO - 10.1093/cid/cir995

M3 - Article

C2 - 22544185

SN - 1058-4838

VL - 54

SP - S261-S265

JO - Clinical infectious diseases

JF - Clinical infectious diseases

IS - 4

ER -

Building Capacity for the Assessment of HIV Drug Resistance: Experiences From the PharmAccess African Studies to Evaluate Resistance Network

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this